Kerr, Shona M. https://orcid.org/0000-0002-4137-1495
Klaric, Lucija https://orcid.org/0000-0003-3105-8929
Muckian, Marisa D.
Cowan, Emma https://orcid.org/0000-0003-1367-930X
Snadden, Lesley
Tzoneva, Gannie
Shuldiner, Alan R.
Miedzybrodzka, Zosia https://orcid.org/0000-0003-2890-8136
Wilson, James F. https://orcid.org/0000-0001-5751-9178
Funding for this research was provided by:
RCUK | Medical Research Council (MC_UU_00007/10)
Wellcome Trust (222060/Z/20/Z-PIII031)
Research Councils UK (MR/R026408/1)
Article History
Received: 29 March 2024
Revised: 22 August 2024
Accepted: 25 September 2024
First Online: 22 October 2024
Competing interests
: AS and GT are employees and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals. LK is an employee of BioAge Labs and holds share options. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.
: Eligible participants were recruited to ORCADES and the Viking Health Study Shetland (VIKING I), now part of Viking Genes, Research Ethics Committee reference 19/SS/0104. Research participants gave written informed consent for research procedures that included electronic health record linkage and DNA sequencing. The data linkage and access to NHS Scotland-originated data for ORCADES and VIKING I was approved by the Public Benefit and Privacy Panel for Health and Social Care (Ref 1718-0380). This research has also been conducted using data from UK Biobank, as part of project number 19655. Frequencies for the <i>ATM</i> and <i>CHEK2</i> variants reported here, and the <i>BRCA2</i> variant c.517-2A>G numbers in Table , were derived from the UK Biobank Whole Genome Sequencing (WGS) project and were obtained from the UK Biobank Allele Frequency Browser (afb.ukbiobank.ac.uk), which was generated by the WGS consortium under the UK Biobank Resource (project ID 52293).